David Ralph Berg

US Patent:

6545027, Apr 8, 2003

Filed:

Jun 7, 1995

Appl. No.:

08/474936

Inventors:

David T. Berg - Beech Grove IN
David S. Calnek - Indianapolis IN
Brian W. Grinnell - Indianapolis IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 3144

US Classification:

514347, 514333, 514443, 514483

Abstract:

A method of modulating NF-kB transcription factor comprising administering to a human in need thereof an effective amount of a compound having the formula wherein R and R are independently hydrogen, âwherein Ar is optionally substituted phenyl; R is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.

US Patent:

6998122, Feb 14, 2006

Filed:

Apr 13, 2000

Appl. No.:

09/719911

Inventors:

Bruce Edward Gerlitz - Indianapolis IN, US
Bryan Edward Jones - Carmel IN, US
David Thompson Berg - Beech Grove IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 38/48
C12N 9/64
C12N 15/00
C12N 5/00
C07H 21/04

US Classification:

424 9464, 435226, 4353201, 435325, 536 232

Abstract:

Novel protein C derivatives are described. These polypeptides retain the biological activity of the wild-type human protein C with substantially longer half-lives in human blood. These polypeptides will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of vascular occlusive disorders, hypercoagulable states, thrombotic disorders and disease states predisposing to thrombosis.

US Patent:

20110207670, Aug 25, 2011

Filed:

Oct 21, 2009

Appl. No.:

13/126474

Inventors:

David Thompson Berg - Beech Grove IN, US
Brian William Grinnell - Indianapolis IN, US
Akanksha Gupta - Indianapolis IN, US

Assignee:

ELI LILLY AND COMPANY - Indianapolis IN

International Classification:

A61K 38/17
C07K 14/435
A61P 13/12

US Classification:

514 154, 530350

Abstract:

The present invention provides a method for preventing and/or treating a patient with acute kidney injury caused by a variety of conditions. The method comprises administering to the patient soluble thrombomodulin variants that do not bind thrombin. In conjunction with standard of care, soluble thrombomodulin variants that do not bind thrombin will prevent or reduce acute kidney injury and subsequent morbidity and mortality.

US Patent:

59487950, Sep 7, 1999

Filed:

Jun 25, 1997

Appl. No.:

8/882711

Inventors:

David Thompson Berg - Beech Grove IN
George Joseph Cullinan - Trafalgar IN
Brian William Grinnell - Indianapolis IN
Mark Alan Richardson - Bloomington IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31445
A61K 3140
C07D40912

US Classification:

514324

Abstract:

Novel benzothiophenes, ##STR1## wherein R. sub. 1, R. sub. 2, and R. sub. 3 are independently --OH, --OCO(C. sub. 1 -C. sub. 6 alkyl), --O(CO)O(C. sub. 1 -C. sub. 6 alkyl), --OCO--Ar, where Ar is phenyl or substituted phenyl, or --O(CO)O--phenyl; and R. sub. 4 is N-pyrrolidinyl, N-piperidinyl, or N-hexamethyleneimino, and intermediates thereof, and the uses and formulations thereof, are provided by the present invention.

US Patent:

57313288, Mar 24, 1998

Filed:

Sep 4, 1996

Appl. No.:

8/708868

Inventors:

David Thompson Berg - Beech Grove IN
Brian William Grinnell - Indianapolis IN
Mark Alan Richardson - Bloomington IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31445
A61K 3140
A61K 3155

US Classification:

514324

Abstract:

A method of inhibiting plasminogen activator inhibitor 1 comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R. sup. 1 and R. sup. 3 are independently hydrogen, --CH. sub. 3, ##STR2## wherein Ar is optionally substituted phenyl; R. sup. 2 is selected from the group consisting of pyrrolidine, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.

US Patent:

55957366, Jan 21, 1997

Filed:

Mar 27, 1995

Appl. No.:

8/411260

Inventors:

David T. Berg - Beech Grove IN
Brian W. Grinnell - Indianapolis IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 3846
A61K 3849
C12N 948
C12N 964

US Classification:

424 9464

Abstract:

The present invention provides derivatives of tissue plasminogen activator that lack the Finger, Growth Factor and Kringle 1 domains and comprise a Kringle 2 domain that is monoglycosylated at a site other than that of t-PA. Using recombinant DNA techniques, an alternate glycosylation sequence is provided within the Kringle 2 domain of these t-PA derivatives. This alternate glycosylation consensus sequence, as well as the glycosylation consensus sequence within the Serine Protease domain, is glycosylated upon the expression and secretion of these molecules from eucaryotic host cells. Thus, a homogeneous population of diglycosylated t-PA derivatives that lack the Finger, Growth Factor and Kringle 1 domains is produced.

US Patent:

59809388, Nov 9, 1999

Filed:

Jun 25, 1997

Appl. No.:

8/882673

Inventors:

David Thompson Berg - Beech Grove IN
George Joseph Cullinan - Trafalgar IN
Brian William Grinnell - Indianapolis IN
Mark Alan Richardson - Bloomington IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 948

US Classification:

424451

Abstract:

The present invention provides methods of inhibiting PAI-1 using benzopyrans.

US Patent:

57806489, Jul 14, 1998

Filed:

Jun 25, 1997

Appl. No.:

8/882674

Inventors:

David Thompson Berg - Beech Grove IN
George Joseph Cullinan - Trafalgar IN
Brian William Grinnell - Indianapolis IN
Mark Alan Richardson - Bloomington IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07D33356
C07D33364
A61K 3138

US Classification:

549 57

Abstract:

Benzothiophenes, and uses and formulations thereof, are provided by the present invention.